Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration

Choroidal Neovascularization Clinical Trial

Official title:

A Prospective Pilot Study of Reduced Fluence Photodynamic Therapy With Visudyne® (Verteporfin) in Combination With Lucentis™ (Ranibizumab) for the Treatment of Age-Related Macular Degeneration

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00473642
• Other study ID #: 2007002
• Status: Completed
• Phase: Phase 4
• Start date: May 2007
• Est. completion date: April 2010

Study information

• Verified date: November 2020
• Source: Oklahoma State University Center for Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this pilot study the researchers will evaluate the safety and efficacy of 50% reduced fluence PDT combination therapy with ranibizumab. The researchers hope to gain information regarding the use of reduced fluence PDT combination therapy. The information gained from this pilot study may prompt further definitive studies comparing the safety and efficacy of both standard fluence PDT combination therapy, reduced fluence PDT combination therapy, and ranibizumab monotherapy.

The study will compare the use of combination therapy with ranibizumab and verteporfin PDT to ranibizumab alone in patients with exudative age-related macular degeneration (AMD). All patients will receive three consecutive monthly treatments with ranibizumab. Patients will be randomized 1:1:1 to 3 groups. Patients randomized to group 1 will receive only ranibizumab. Patients randomized to group 2 will also receive one treatment with reduced fluence (50% fluence) verteporfin PDT at day 0. Patients randomized to group 3 will also receive one treatment with standard fluence verteporfin PDT. All patients will also be evaluated for possible retreatment with ranibizumab and verteporfin PDT according to established criteria. Thirty patients will be recruited from one U.S. sites. Randomization will occur at the time of entry into the study. Follow-up will continue until month 12 (from day 0) in all subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: April 2010
• Est. primary completion date: May 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

1. Male or Female Patients > 50 years of age.

2. Patients with primary subfoveal CNV secondary to AMD documented on IVFA and/or OCT.

3. Patient with BCVA of 20/40 to 20/320 in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. See definition of ETDRS charts.

4. If both eyes are eligible, only one eye will be evaluated in the study. The eye with lesser visual acuity will be selected as the study eye.

5. Patients must be able and willing to provide written informed consent.

Exclusion Criteria:

1. Patients receiving prior treatment in the study eye with verteporfin, any focal laser photocoagulation, vitrectomy, or intravitreous injection of antiangiogenic medications, including triamcinolone, pegaptanib, bevacizumab, or ranibizumab.

2. Neovascular membrane from any other retinal disease such as myopic degeneration, histoplasmosis, retinal angiomatous proliferation, or other ocular inflammatory disease.

3. Choroidal neovascular membrane greater than 9 disc diameters in size.

4. Previous posterior vitrectomy in the study eye.

5. Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the study period.

6. Pregnant women or premenopausal women not using adequate contraception.

7. History of allergy to fluorescein, Visudyne, Lucentis.

8. Inability to comply with study or follow up procedures.

Related Conditions & MeSH terms

• Age-Related Maculopathy
• Choroidal Neovascularization
• Macular Degeneration
• Neovascularization, Pathologic

Intervention

Drug:
• Ranibizumab
intravitreal administered ranibizumab 0.5 mg in 0.05 mL
• Verteporfin
Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
• Verteporfin
Verteporfin with standard fluence photodynamic therapy (50 J/cm2)

Locations

Country	Name	City	State
United States	Eagle Mountain Vision	Tulsa	Oklahoma

Sponsors (2)

Lead Sponsor	Collaborator
Oklahoma State University Center for Health Sciences	Novartis

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change in BCVA of ETDRS Letters From Baseline at 12 Months	Visual acuity is often measured using a chart called the ETDRS chart (Early Treatment Diabetic Retinopathy Study). A letter score is calculated based on the number of letters that can be correctly identified from specified distances. Higher letter scores correspond to better visual acuity. Lower letter scores mean poorer visual acuity. In this study the baseline visual acuity in letters is subtracted from the visual acuity in letters measured at the 12 month visit providing a letter score of vision gain or vision loss.	12 months
Primary	Mean Letters Gained of Best Corrected Visual Acuity Using ETDRS Protocol	Visual acuity is often measured using a chart called the ETDRS chart (Early Treatment Diabetic Retinopathy Study). A letter score is calculated based on the number of letters that can be correctly identified from specified distances. Higher letter scores correspond to better visual acuity. Lower letter scores mean poorer visual acuity. In this study the baseline visual acuity in letters is subtracted from the visual acuity in letters measured at the 12 month visit providing a letter score of vision gain or vision loss.	12 months
Secondary	Time to First Retreatment After Loading Doses		12 months
Secondary	Average Number of PDT Retreatments Over 12 Months		12 months
Secondary	Central Macular Thickness Reduction on OCT		12 months
Secondary	Average Number of Ranibizumab Retreatments Over 12 Months		12 months